IBLcomplementsits
dementiaMarkerrange

Furtherimprovementinthediagnosisofneurodegenerativediseases

Alongwithamyloid-βplaques,theformationoftaufibrilswithinthenervecells,particularlyinthecerebralcortexandnotablyinthelimbiclobe,isanotherpathologicalhallmarkofAlzheimer"sdisease.TheconcentrationofTauintheCSFisamarkerofneuronalcelldeath.InAlzheimer"sdisease,however,itincreasesonlyatalaterstageofthediseasewhenthepatientalreadydisplayssignificantcognitiveimpairment.Therefore,thedeterminationoftotaltauinCSFisimportantforthediagnosisofAlzheimer"sdiseaseinadditiontothedeterminationofamyloidβ-peptides.However,increasedtaulevelsarefoundinotherneurodegenerativediseasesaswell.Thesedisordersaregenerallyreferredtoastauopathiesandinclude,interalia,frontotemporallobardegeneration(FTLD),Pick"sdiseaseandcorticobasaldegeneration(CBD).TaulevelsaremarkedlyelevatedinCreutzfeldt-Jakobdisease.

ThehTAUtotalELISAfromAnalytikJena,manfuacturedbyAJRoboscreenanddistributedbyIBLInternational,wasoptimizedsothatitcanbeprocessedinparallelwiththeIBLAmyloid-βCSFELISA.

Asthegraphbelowshows,thehTAUtotalELISAfromAnalytikJena,manufacturedbyAJRoboscreenanddistributedbyIBLInternational,correlatessuperblywiththeINNOTEST^®hTAU.

ClinicalvalidationoftheTAUtotalELISAwasperformedattheUniversityHospitalErlangenintheCSFLaboftheDepartmentofPsychiatryandPsychotherapy(Prof.Dr.Lewczuk).TaulevelsinthecerebrospinalfluidofpatientswithAlzheimer"sdiseaseandmildcognitiveimpairment(collectivelyAD(n=72)andcontrolsubjects(n=41))showhighlysignificantdifferencesbetweenthegroups.

Naturally,theTAUtotalELISA,justlikeourAmyloid-βCSFELISAs,displaysanexcellentanalyticalprecisionwithaninter-assayvarianceof<5% (Table 1), intra-assay variance of <5% (Table 2) and inter- LOT and operator variance of <6% (Table 3).

	TAUtotalELISA
Sample	MW	CV
	[pg/mL]	[%]
1	182	4.7
2	315	4.4
3	343	4.3

	TAUtotalELISA
Sample	MW	CV
	[pg/mL]	[%]
1	179	4.5
2	307	2.7
3	338	2.1

	TAUtotalELISA
Sample	MW	CV
	[pg/mL]	[%]
1	180	5.7
2	311	4.4
3	342	5.6

AdditionaladvantagesofourELISAare:

• Dayassay(4hours)
• SameprotocolasAmyloid-βCSFELISAs
• Kitcontrols
• Itlendsitselftoautomation

GeneralInformation

In2010,thenumberofdementiapatientsworldwidewasestimatedat36million.Assuminganongoinglackofsufficientpreventiveandcurativetreatments,thisisexpectedtodoubleevery20years.Alzheimer’sDiseaseaccountsforroughly60‐70%ofalldementiacases.Bothprevalenceandincidenceincreasewithage.Prevalenceisaround1%
inthoseaged65‐69,andmorethan30%inthoseaged90orolder.

ThefirstcaseofAlzheimer’sDiseasewasdefinedandreportedin1907byGermanscientistDr.AloisAlzheimer.HedescribedtwohallmarksoftheDisease‐theplaquesandtanglesinthebrainsofAlzheimer’spatients.TheplaquesareformedbyAmyloid-betapeptidedepositsandthetanglesarecomposedofhyperphosphorylatedTauproteins.

Amyloidosisoccursasearlyasthepreclinicalstage.Thefirstcognitivedeficitscanmanifestthemselvesinthemildcognitiveimpairment(MCI)stage,whileinthedementiastagepatientsareunabletodoanyworkordailychores.
TheconcentrationofTAUinCSFisthereforerecognizedasaonebiomarkerindiagnosingAlzheimer’sDisease.
Moreover,anumberofindependentstudiesshowedthatcombiningTAU‐proteinandamyloid‐beta(1‐42)levelswillenhancespecificityandsensitivityofdiagnosisofAlzheimer’sDisease,whichisfurtherenhancedwhencombiningTAUlevelstoAmyloid-betaratiomeasurement.

ForconcretedatapleaseconsulttheInstructionforUseinthedownloadboxontherightside. IBL我们的液体处理专业知识可实现高度复杂的分子诊断技术的可靠自动化，例如细胞遗传学（核型分析和FISH）和分子细胞遗传学（aCGH /阵列比较基因组杂交），其应用范围从代谢疾病和癌症到生殖遗传学和移植药物。该产品组合涵盖了细胞遗传学和分子细胞遗传学工作流程的关键阶段，从标准化工作站，经过验证的应用程序和专用用户界面，到与Tecan Labwerx合作开发的高度定制的平台。